RxDoctor Payments Data

Ayman Akkad, MD

Internal Medicine · Lutherville, MDNPI 1639126113

Payments from drug & device makers

$790in general payments, 2019–2025

Across 50 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$297
  • Ascensia Diabetes Care US Inc.$90
  • Novo Nordisk$65
  • Pfizer$48
  • Astellas Pharma US Inc$43
  • Merck$36
  • plus $211 from 12 others

What the payments were for

  • Food & beverage$78499%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$790 in reported general payments places this provider in the 70th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$290,290
Medicare patients
546
Services billed
4,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban147$139,538
OzempicSemaglutide35$54,379
TrulicityDulaglutide34$45,968
XareltoRivaroxaban33$41,160
JanuviaSitagliptin Phosphate36$39,585
Tresiba Flextouch U-200Insulin Degludec26$23,999
JardianceEmpagliflozin13$18,805
FarxigaDapagliflozin Propanediol12$18,021
MyrbetriqMirabegron12$16,341
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$15,779
TradjentaLinagliptin12$15,463
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$14,232
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$12,621
OxycontinOxycodone Hcl12$9,047
Fluticasone-SalmeterolFluticasone Propion/Salmeterol43$8,600

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$48$139,538147 claims
Novo NordiskOzempic$65$54,37935 claims
Lilly USA, LLCTrulicity$13$45,96834 claims
Johnson & JohnsonXarelto$14$41,16033 claims
MerckJanuvia$36$39,58536 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$12$39,56236 claims
AstraZenecaFarxiga, Breztri Aerosphere$297$30,64226 claims
Astellas Pharma US IncMyrbetriq$43$16,34112 claims
AbbVieSynthroid$22$3,07644 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Lutherville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →